Improving prognosis after spontaneous intracerebral hemorrhage using clinical, blood, and imaging markers
Official title: Improving the Prognosis for Cerebral Hemorrhage A Study of Clinical, Biological, and Imaging Markers
Run by University Hospital, Tours · NCT07444853 · Data updated 2026-11-12
This project will try combining clinical data, blood samples, and brain scans to find markers that predict outcomes for adults admitted with spontaneous intracerebral hemorrhage.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 10000 (estimated) |
| Sponsor | University Hospital, Tours Academic / other |
| Locations | 4 sites (Angers and 3 other locations) |
| Status | Recruiting |
| Started | April 9, 2026 |
| Main results expected | April 2036 |
| Study ends | April 2036 |
| Registry record updated | May 6, 2026 |
| Trial ID | NCT07444853 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults (age ≥18) who are emergently admitted to a participating center with spontaneous intracerebral hemorrhage confirmed by the first in-hospital CT or MRI and who can provide non-opposition to participation are ideal candidates.
✕Probably not a fit
Patients whose hemorrhage is secondary to a known cause (for example vascular malformation, tumor, hemorrhagic infarct, or recent head trauma), those imaged first at non-participating centers, or those under legal protection/guardianship are not eligible and unlikely to benefit from this cohort.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a prospective, multicenter national cohort enrolling adults with spontaneous intracerebral hemorrhage to collect standardized clinical, biological, and imaging data. A centralized, harmonized biobank will store samples aimed at biomarkers of inflammation, hematoma resorption, and genetic susceptibility. An interoperable imaging database will enable quantitative measures such as hematoma volume, expansion, and perihematomal edema and track their evolution over time. The protocol also documents acute care practices, including adherence to the INTERACT-3 care bundle, and is intended as a platform for translational work and preparation of future stratified interventional trials.
Why it matters
Potential benefit: If successful, the work could help clinicians identify patients at higher risk earlier and guide more personalized acute and follow-up care to improve outcomes.
How similar studies have gone: Evidence-based care bundles such as INTERACT-3 have shown benefit for early blood-pressure and general acute care management, but using combined clinical, biological, and imaging biomarkers for prognostic stratification remains an emerging approach with limited widescale validation.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age ≥ 18 years; * Emergency admission to a participating center, with spontaneous intracerebral hemorrhage confirmed by the first brain imaging (CT or MRI) performed at the time of initial treatment; * Obtaining non-opposition Exclusion Criteria: * First brain imaging performed outside a center participating in the study (e.g., peripheral center not recruiting); * Intracerebral hemorrhage secondary to another identified condition, including: * vascular malformation (aneurysm, arteriovenous malformation, cavernoma, etc.); * intracranial tumor; * hemorrhagic transformation of a cerebral infarction; * recent head trauma. * Patient under legal protection; * Patient under guardianship or conservatorship.
Where it's running
-
University hospital
Tours, France Recruiting -
university hospital, Angers
Angers, France Not yet recruiting -
university hospital, Lille
Lille, France Not yet recruiting -
University hospital, Toulouse
Toulouse, France Not yet recruiting
Study contacts
- Study coordinator: Marco PASI, Pr
- Email: m.pasi@chu-tours.fr
- Phone: 2.47.47.80.21
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Sleep patterns to help predict waking from brain injury
Doctors are testing whether brain activity during sleep can help predict when a person with a serious brain injury will regain awareness.
-
Understanding how sensory brain signals vary in people with and without neurodevelopmental disorders
This study tests whether people with neurodevelopmental disorders show more variation in brain responses to sensory stimulation than people without these disorders.
-
Multiomics (genome plus metabolome) approach for adults with phenylketonuria
This project will test whether combining whole-genome sequencing from saliva and non-targeted blood metabolomics can find genetic and metabolic patterns linked to symptoms in adults who were treated for phenylketonuria from birth.
-
Communication support for ventilated intensive care patients
This project will try an eye-tracking tablet (JIB-Tours care) to help conscious, ventilated adults in ICU who cannot speak communicate with caregivers and family.
-
Morphine removal and kidney filtering in adults with sickle cell crises in intensive care
This project will test how quickly morphine is cleared from the body in adults with sickle cell disease admitted to intensive care for vaso-occlusive crisis or acute chest syndrome, and whether faster kidney filtering leads to lower morphine levels.
-
Apneic oxygenation with high-flow nasal oxygen during intubation in hypoxemic ICU patients
This study tests whether using high-flow nasal oxygen during the pause between laryngoscopy and successful intubation helps prevent severe low oxygen levels in ICU patients with hypoxemic respiratory failure.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.